Search results
Results from the WOW.Com Content Network
The Medicaid Drug Rebate Program is a program in the United States that was created by the Omnibus Budget Reconciliation Act of 1990 (OBRA'90). The program establishes mandatory rebates that drug manufacturers must pay state Medicaid agencies related to the dispensing of outpatient prescription drugs covered by Medicaid.
State Medicaid programs must administer their coverage of prescription outpatient drugs in a manner that accounts for participation in the 340B Drug Pricing Program. Typically, state Medicaid programs obtain rebates for dispensed outpatient prescription drugs through the Medicaid Drug Rebate Program. However, duplicate discounts are prohibited.
Also in 2009, the company and its subsidiary UDL agreed to pay $118 million to settle a suit filed under the False Claims Act in which Mylan/UDL and two other companies were accused of underpaying states under the Medicaid Drug Rebate Program. The program requires drug companies to give rebates to states under Medicaid and the rebates are ...
About 17% of women ages 18 to 49 on Medicaid who needed treatment for drug or alcohol use failed to receive it in 2021, the report added. ... David Robinson is the New York State Team health care ...
The share of Medicaid costs financed by state taxpayers has jumped by 53% over the past five years and currently consumes about 28% of all state operating funds. “New York should stop abusing ...
False Claims Act, Medicaid Rebate Statute 2007 Purdue Pharma [15] $601 million Off-label promotion Oxycontin: False Claims Act 2010 Allergan [16] $600 million Off-label promotion Botox: False Claims Act, FDCA 2010 AstraZeneca [17] $520 million Off-label promotion, kickbacks Seroquel: False Claims Act 2007 Bristol-Myers Squibb [18] $515 million
Elderly Pharmaceutical Insurance Coverage (EPIC) [1] [2] [3] ("New York State's Senior Prescription Plan") [4] was designed so that personal/out-of-pocket costs for medicines are reduced or largely paid for program participants by the state. [1] Members are also given assistance with Medicare Part D. [5]
The Medicaid drug rebate for brand name drugs, paid by drug manufacturers to the states, is increased to 23.1% (except for the rebate for clotting factors and drugs approved exclusively for pediatric use, which increases to 17.1%), and the rebate is extended to Medicaid managed care plans; the Medicaid rebate for non-innovator, multiple source ...